Abstract 4438
Background
Choline Positron Emission Tomography – Computed Tomography (Choline PET/CT) allows for the diagnosis of oligometastatic (OM) Prostate Cancer (PCa) recurrence that could be treated with a curative intent. The aim of the study was to evaluate the different therapeutic approaches and outcomes for first OM recurrence.
Methods
This multi-institutional, retrospective study included patients with a hormone-sensitive biochemical PCa recurrence after an initial curative local treatment, and with at least 1 to 5 Choline PET/CT-diagnosed metastatic lesions. Primary endpoint was Biochemical Recurrence Free Survival (BRFS). Secondary endpoints were Metastatic Recurrence-Free Survival (MRFS) and Androgen Deprivation Therapy-Free Survival (ADT-FS).
Results
Between October 2012 and December 2016, 177 patients were included. Sixty-eight patients (38.4%) received an ADT alone, 72 (40.7%) received an External Beam Radiation Therapy (EBRT) – ADT association, 28 (15.8%) received an EBRT, 6 (3.4%) received a surgery, and 2 (1.1%) received a surgery with ADT. Median follow-up was 49 months [95%CI, 44.3-53.4]. Among patients who received non-standard treatment, 55% avoided long-term ADT. Grade 3 acute and late toxicities were rare (0.8% and 2.5% respectively). The median BRFS, MRFS and ADT-FS were 42 [95%CI, 37-51], 61 [95%CI, 45-81], and 53 [95%CI, 45-60] months, respectively. In multivariate analysis, concomitant ADT with MDT and "regional" EBRT combined with MDT significantly improved BRFS (p < 0.0001 and p = 0.0113 respectively) and MRFS (p = 0.0005 and p = 0.0013 respectively). In multivariate analysis, a PSA-doubling time of > 3 months had a statistically significant positive impact on MRFS (p = 0.0496) and ADT-FS (p = 0.0007). The overall and disease specific survivals were 87% and 97% respectively at 5 years. The median incidence of castration resistant PCa was 80 months.
Conclusions
In patients with hormone-sensitive OM PCa recurrence after initial local treatment, BRFS and MRFS were significantly improved when concomitant ADT and "regional" EBRT were combined with MDT.
Clinical trial identification
OMPPC-IPC 2018-059.
Editorial acknowledgement
Legal entity responsible for the study
Institute Paoli-Calmettes.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract